AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33219590 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled pressure from a sphygmomanometer inflated to 100 mmHg (N=18)
Number of subjects: 59
Study 33219590 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of heat and pressure (N=20)
Number of subjects: 59
Study 33219590 — intervention group
Group type: COMPARATOR
Intervention: Standard tourniquet around the upper arm (control)
Number of subjects: 59
Study 32221332 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium picosulfate/magnesium citrate (PSMC) preparation-Bowklean
Number of subjects: 631
Study 32221332 — intervention group
Group type: COMPARATOR
Intervention: Klean-Prep/Dulcolax
Number of subjects: 631
Study 35768736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cefazolin
Number of subjects: 16
Study 35768736 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clindamycin
Number of subjects: 16
Study 34405393 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) plus oral arsenic (realgar-indigo naturalis formula)
Number of subjects: 212
Study 34405393 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) plus arsenic trioxide
Number of subjects: 212
Study 34405393 — intervention group
Group type: EXPERIMENTAL
Intervention: PML-RARA transcript level of ≥6.5% at the end of induction therapy
Number of subjects: 212
Study 35461558 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 1106
Study 35461558 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 1106
Study 32067615 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 542
Study 32067615 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 542
Study 32067615 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 542
Study 32067615 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PPIs)
Number of subjects: 542
Study 35162375 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D-3L
Number of subjects: 577
Study 33397316 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative and Skills‐building Intervention (NSI)
Number of subjects: 208
Study 33397316 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 208
Study 32203696 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour bed boost
Number of subjects: 1208
Study 32203696 — intervention group
Group type: COMPARATOR
Intervention: Conventional whole breast radiotherapy
Number of subjects: 1208
Study 34687036 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive aerobic exercise (PAE) for 24 weeks, 2 supervised sessions per week, 30–60 minutes at 65–95% of maximum heart rate.
Number of subjects: 86
Study 34687036 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (24 weeks of habitual lifestyle) followed by PAE.
Number of subjects: 86
Study 34687036 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive aerobic exercise (PAE) for 24 weeks.
Number of subjects: 86
Study 34711072 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care services
Number of subjects: 2494
Study 34711072 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2494
Study 33354979 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Brief Behavioural Change Counselling (ABC tool)
Number of subjects: 6
Study 33354979 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Brief Behavioural Change Counselling (ABC tool) - sub-scores
Number of subjects: 6
Study 35297691 — intervention group
Group type: EXPERIMENTAL
Intervention: Equation group (EG) using portable method to measure sweat rate (SR)
Number of subjects: 32
Study 35297691 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group (VG) using portable method to measure sweat rate (SR)
Number of subjects: 32
Study 35297691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both groups
Number of subjects: 32
Study 33020898 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone 100 mg
Number of subjects: 14
Study 33020898 — intervention group
Group type: COMPARATOR
Intervention: Oral progesterone 400 mg
Number of subjects: 14
Study 33020898 — intervention group
Group type: COMPARATOR
Intervention: Matching transdermal/oral placebo
Number of subjects: 14
Study 33104729 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar condition
Number of subjects: 20
Study 33104729 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study 35751508 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash (MW)
Number of subjects: 32
Study 35751508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 33357674 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased body weight (BW) trajectories (up to 22.5% above recommended target)
Number of subjects: 36
Study 33357674 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased body weight (BW) trajectories
Number of subjects: 36
Study 33357674 — intervention group
Group type: EXPERIMENTAL
Intervention: Feed-restricted birds
Number of subjects: 36
Study 33357674 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted birds
Number of subjects: 36
Study 35133701 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mouth rinse (Lactobacillus acidophilus, Lactobacillus rhamnosus, Bifidobacterium longum, Saccharomyces boulardii)
Number of subjects: 60
Study 35133701 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouth rinse
Number of subjects: 60
Study 35133701 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mouth rinse
Number of subjects: 60
Study 32559734 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic-diet with low-fructose for 8 weeks
Number of subjects: 50
Study 36052175 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST) high volume (3 sets per exercise) + photobiomodulation therapy (PBMt)
Number of subjects: 48
Study 36052175 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (ST) low volume (1 set per exercise) + photobiomodulation therapy (PBMt)
Number of subjects: 48
Study 36052175 — intervention group
Group type: COMPARATOR
Intervention: Strength training (ST) high volume (3 sets per exercise) + placebo
Number of subjects: 48
Study 36052175 — intervention group
Group type: COMPARATOR
Intervention: Strength training (ST) low volume (1 set per exercise) + placebo
Number of subjects: 48
Study 32989456 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (≥5 years)
Number of subjects: 752469
Study 32989456 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (intention-to-treat)
Number of subjects: 752469
Study 32989456 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (per-protocol)
Number of subjects: 752469
Study 32989456 — intervention group
Group type: COMPARATOR
Intervention: Previous case-control analytical approaches
Number of subjects: 752469
Study 35675605 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic osmotic cervical dilator
Number of subjects: 307
Study 35675605 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol
Number of subjects: 307
Study 34169551 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct use of deproteinized bovine bone mineral (DBBM) and native bilayer collagen membrane (NBCM)
Number of subjects: 66
Study 34169551 — intervention group
Group type: COMPARATOR
Intervention: Surgical debridement
Number of subjects: 66
Study 33292887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (42g/day in low fat muffins)
Number of subjects: 28
Study 33292887 — intervention group
Group type: COMPARATOR
Intervention: Sucrose (42g/day in low fat muffins)
Number of subjects: 28
Study 33292887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose and Sucrose (both types consumed)
Number of subjects: 28
Study 35987208 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care viral load testing every 3 months, targeted drug resistance mutation testing, and clinical decision support.
Number of subjects: 704
Study 35987208 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 704
Study 35987208 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care viral load testing.
Number of subjects: 704
Study 35987208 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted drug resistance mutation testing in intervention participants.
Number of subjects: 704
Study 33986070 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration treatment strategy (antibiotics may be stopped as early as day 3 if respiratory cultures are negative, and day 5 if positive)
Number of subjects: 460
Study 33986070 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care duration arm (antibiotics for at least 8 days)
Number of subjects: 460
Study 33986070 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration treatment strategy
Number of subjects: 460
Study 35587457 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly intramuscular (IM) 17 hydroxyprogesterone (17‐OHP)
Number of subjects: 0
Study 35587457 — intervention group
Group type: COMPARATOR
Intervention: 17‐OHP
Number of subjects: 0
Study 34459574 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction exercise (BFR) for 4 weeks prior to surgery
Number of subjects: 10
Study 34459574 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (no exercise)
Number of subjects: 10
Study 34459574 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction exercise (BFR)
Number of subjects: 10
Study 35261049 — intervention group
Group type: EXPERIMENTAL
Intervention: High-performance inulin (HPI)
Number of subjects: 75
Study 35261049 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (OEI)
Number of subjects: 75
Study 35261049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 35450573 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 150 mg
Number of subjects: 28
Study 35450573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 32697847 — intervention group
Group type: EXPERIMENTAL
Intervention: TEACH intervention (nurse care manager, interactive electronic registry, opioid education, academic detailing, access to addiction specialists)
Number of subjects: 187
Study 32697847 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 187
Study 32697847 — intervention group
Group type: EXPERIMENTAL
Intervention: TEACH intervention
Number of subjects: 187
Study 32369569 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen Matrix Seal (CMS)
Number of subjects: 28
Study 32369569 — intervention group
Group type: COMPARATOR
Intervention: Collagen Sponge (CS)
Number of subjects: 28
Study 35469810 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation (WATER)
Number of subjects: 217
Study 35469810 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquablation (WATER II)
Number of subjects: 217
Study 34397949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with dexmedetomidine (RD)
Number of subjects: 102
Study 34397949 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with nalbuphine (RN)
Number of subjects: 102
Study 34397949 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (RC)
Number of subjects: 102
Study 34686445 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 258
Study 34686445 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 258
Study 33471629 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Way Prayer Meditation (TWPM)
Number of subjects: 134
Study 33471629 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 134
Study 36111381 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of DIM (300 mg of DIM-BR®) daily for 30 days
Number of subjects: 60
Study 33901103 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 4295
Study 35431172 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg monthly for 52 weeks
Number of subjects: 161
Study 35431172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 32579613 — intervention group
Group type: EXPERIMENTAL
Intervention: NoHoW method
Number of subjects: 109
Study 32579613 — intervention group
Group type: EXPERIMENTAL
Intervention: Kalman imputation
Number of subjects: 109
Study 32579613 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation
Number of subjects: 109
Study 32579613 — intervention group
Group type: EXPERIMENTAL
Intervention: Kalman method and NoHoW method
Number of subjects: 109
Study 34544808 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month salsa dance training intervention, 2 weekly 1-hour sessions
Number of subjects: 180
Study 34544808 — intervention group
Group type: COMPARATOR
Intervention: Regular fitness circuit training
Number of subjects: 180
Study 34544808 — intervention group
Group type: COMPARATOR
Intervention: Control group (passive comparator)
Number of subjects: 180
Study 32539069 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-Distributed HIV Self-tests
Number of subjects: 1340
Study 32539069 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1340
Study 34044584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus enzalutamide
Number of subjects: 0
Study 34044584 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide plus placebo
Number of subjects: 0
Study 32522126 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole intervention
Number of subjects: 0
Study 35780483 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based mandala activity (3 sessions)
Number of subjects: 170
Study 32590057 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal mindfulness
Number of subjects: 105
Study 32075832 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended care programme (combining face-to-face consultations with web-based self-learning)
Number of subjects: 1200
Study 32075832 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1200
Study 32186977 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef protein supplementation (BEEF), 25 g daily for 8 weeks
Number of subjects: 6
Study 32186977 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef protein supplementation (BEEF)
Number of subjects: 6
Study 32186977 — intervention group
Group type: COMPARATOR
Intervention: Isoenergetic carbohydrates (CHO) supplement
Number of subjects: 6
Study 33211769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping therapy with negative pressure of 400 mmHg for 15 minutes, twice a week, for 4 weeks
Number of subjects: 18
Study 36724180 — intervention group
Group type: EXPERIMENTAL
Intervention: Early active LV unloading
Number of subjects: 421
Study 36724180 — intervention group
Group type: COMPARATOR
Intervention: Delayed active LV unloading
Number of subjects: 421
Study 33744613 — intervention group
Group type: COMPARATOR
Intervention: Synb
Number of subjects: 1200
Study 33744613 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 1200
Study 33744613 — intervention group
Group type: COMPARATOR
Intervention: Prob 2
Number of subjects: 1200
Study 33744613 — intervention group
Group type: COMPARATOR
Intervention: Prob 1
Number of subjects: 1200
Study 33744613 — intervention group
Group type: EXPERIMENTAL
Intervention: NC
Number of subjects: 1200
Study 32286934 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 0
Study 35446303 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise program (n=22)
Number of subjects: 49
Study 35446303 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=27)
Number of subjects: 49
Study 34176448 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone (BUP-NX)
Number of subjects: 79
Study 34176448 — intervention group
Group type: COMPARATOR
Intervention: Extended-Release Injectable Naltrexone (XR-NTX)
Number of subjects: 79
Study 33010767 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 50
Study 33010767 — intervention group
Group type: COMPARATOR
Intervention: Conventional instrumentation (CI)
Number of subjects: 50
Study 36257701 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational screening intervention implemented in 15 primary care practices
Number of subjects: 85697
Study 36257701 — intervention group
Group type: COMPARATOR
Intervention: Control group (practices not receiving the educational intervention)
Number of subjects: 85697
Study 36257701 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 85697
Study 34854982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradialytic cycling (IDC), 30 min of moderate intensity (RPE 12-14), thrice weekly for 6 months
Number of subjects: 20
Study 34854982 — intervention group
Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 20
Study 36178636 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily step count
Number of subjects: 226
Study 36178636 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 226
Study 36178636 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 226
Study 34105317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0
Study 34105317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36228695 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe (ENDO-AID OIP-1)
Number of subjects: 370
Study 36228695 — intervention group
Group type: COMPARATOR
Intervention: Standard exploration (control)
Number of subjects: 370
Study 34183742 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic exercise (IG)
Number of subjects: 0
Study 34183742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (NG)
Number of subjects: 0
Study 34183742 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study 36434605 — intervention group
Group type: EXPERIMENTAL
Intervention: Saga Stories in health talks
Number of subjects: 450
Study 36434605 — intervention group
Group type: COMPARATOR
Intervention: Standard health talk (Control)
Number of subjects: 450
Study 34798808 — intervention group
Group type: EXPERIMENTAL
Intervention: Total NT-proBNP
Number of subjects: 382
Study 34798808 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 382
Study 34798808 — intervention group
Group type: EXPERIMENTAL
Intervention: Ang2
Number of subjects: 382
Study 34798808 — intervention group
Group type: EXPERIMENTAL
Intervention: BMP10
Number of subjects: 382
Study 36241492 — intervention group
Group type: EXPERIMENTAL
Intervention: Malkia Klabu intervention (girl-friendly drug shops)
Number of subjects: 0
Study 35768875 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive text messaging intervention (iTAB-CV) with daily texts for 2 months, followed by either high or low booster texts for an additional 2 months
Number of subjects: 200
Study 35768875 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring of medication taking, mood, and home blood pressure
Number of subjects: 200
Study 35768875 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive text messaging intervention (iTAB-CV)
Number of subjects: 200
Study 35768875 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring alone
Number of subjects: 200
Study 33143655 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood group A
Number of subjects: 61
Study 33143655 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood group A (after adjustment)
Number of subjects: 61
Study 35672892 — intervention group
Group type: EXPERIMENTAL
Intervention: Yinhua Miyanling tablets (YMT) 2 g qid orally
Number of subjects: 211
Study 35672892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dummy YMT) 2 g qid orally
Number of subjects: 211
Study 34087717 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative combi-elastography (ARIETTA 850, Hitachi Healthcare)
Number of subjects: 94
Study 34087717 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular invasion (MVI)
Number of subjects: 94
Study 34087717 — intervention group
Group type: EXPERIMENTAL
Intervention: F index
Number of subjects: 94
Study 34087717 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model based on laboratory tests, MVI, and F index
Number of subjects: 94
Study 32993256 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol patient‐controlled intravenous analgesia (0.15 mg/kg)
Number of subjects: 100
Study 32993256 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil patient‐controlled intravenous analgesia (1.5 μg/kg)
Number of subjects: 100
Study 32993256 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol patient‐controlled intravenous analgesia
Number of subjects: 100
Study 36156262 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32614046 — intervention group
Group type: EXPERIMENTAL
Intervention: SocialVille (online social cognition training)
Number of subjects: 108
Study 32614046 — intervention group
Group type: COMPARATOR
Intervention: Active control (computer games)
Number of subjects: 108
Study 32788417 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT) applied in inhibitory mode
Number of subjects: 7
Study 32788417 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 7
Study 35466481 — intervention group
Group type: EXPERIMENTAL
Intervention: BB2603-1 (0.01% terbinafine)
Number of subjects: 46
Study 35466481 — intervention group
Group type: COMPARATOR
Intervention: Lamisil AT 1% spray
Number of subjects: 46
Study 35466481 — intervention group
Group type: COMPARATOR
Intervention: BB2603-1 vehicle control
Number of subjects: 46
Study 35466481 — intervention group
Group type: COMPARATOR
Intervention: BB2603-1 vehicle
Number of subjects: 46
Study 33273276 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep cervical plexus block
Number of subjects: 66
Study 33273276 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 66
Study 36686308 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescein + methylene blue
Number of subjects: 130
Study 36686308 — intervention group
Group type: COMPARATOR
Intervention: Tc‐99 m sulfur colloid + methylene blue
Number of subjects: 130